The MErCuRIC Phase I trial was presented at the ESMO 2016 Congress in Copenhagen (7 – 11 Oct 2016). MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours (Poster: 480P) R. Wilson, M. Middleton, J. Houlden, S. Van Schaeybroeck, C. Rolfo, E. Elez, J. Taieb , […]
This author has yet to write their bio.Meanwhile lets just say that we are proud mercuric contributed a whooping 46 entries.
Entries by mercuric
Technologies to isolate and analyse liquid biopsy samples are rapidly evolving. MErCuRIC researcher Federica Di Nicolantonio discusses the technique in this video produced with ESMO.
The summer 2016 newsletter for the European Patients’ Academy (EUPATI) is now available. In this issue, you can access the Patient Expert Training Course, now available in English, as well as learn about the growing national EUPATI teams that function as patient involvement groups locally.
Congratulations to Prof. Alberto Bardelli of UNITO on his election as President of the European Association for Cancer Research (EACR)! You can read more here.
While the ever-advancing landscape of precision medicine in oncology undoubtedly brings fresh hope for patients, it also poses many yet unanswered questions as to how we move forward, without the real risk of burn-out of those who treat them – particularly with regards to the up-and- coming generation of young oncologists, the future of our profession and practice. Established […]
In June 2016, the Northern Ireland Cancer Research Consumer Forum and its Bowel Cancer Research Interest Group hosted a public event – ‘Delivering 21st Century Medicine for bowel cancer patients’. A MErCuRIC poster was displayed at the event in Belfast. The event was opened by a member of the Local Assembly and speakers included MErCuRIC researcher […]
MErCuRIC researchers from RCSI, BHSCT, QUB and PDUM presented results from their other research projects in colorectal cancer at the American Society of Clinical Oncology (ASCO) 2016 Annual meeting in Chicago, 03 – 07 June. A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a […]
On 29 June 2016, MErCuRIC partners from BHSCT and QUB will participate in a free public event on bowel cancer. Prof. Mark Lawler (QUB) will speak at the event, which will include patients, advocates and researchers as attendees.
‘Validation of a MEK/MET-specific NGS panel for early phase trial interrogation‘ and ‘Upregulation of the MET transcript is consistently associated with invasion and tumor budding in colorectal cancer‘ were presented at the AACR Annual Meeting on 18 Apr 2016 in New Orleans. Mariangela Russo from UNITO also presented related work (Abstract 878). Validation of a MEK/MET-specific […]
MErCuRIC partner hospital Hôpital Georges-Pompidou is hosting a Colorectal Cancer Information Day, open to the public on Tuesday 09 March. The event will include a simulation on the Da Vinci surgical robot and a Giant Colon to see what your own gut looks like! Registration is required at 01 56 09 39 82 or firstname.lastname@example.org
- Reflections from EAPM 2017 where MErCuRIC PPI was HighlightedDecember 14, 2017 - 8:11 am
- EuropaColon Patients’ Survey on The Unmet Needs of Patients Living with Metastatic Colorectal CancerDecember 4, 2017 - 3:35 pm
- MErCuRIC team from the Università degli Studi di Torino publish in NatureNovember 30, 2017 - 8:54 am
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.